Immunoscintigraphy using Tc-99m-labelled MAbs (Schwarz & Steinstraesser, 1987) is becoming a routine diagnostic method for the in vivo detection of tumours (Baum et al., 1988 (Baum et al., , 1989 Kroiss et al., 1989; Lind et al., 1989) and inflammatory processes (Joseph et al., 1987 (Joseph et al., , 1988a Becker et al., 1989) . In contrast, radioimmunotherapy using MAbs tagged with 1-131 or Y-90 has not been accepted as a treatment modality in oncology despite a few encouraging early reports (Epenetos & Kosmas, 1989; Epenetos, 1987) . This is mainly due to the small amounts of radiolabelled MAbs bound to the tumour site and the unfavourable whole body distribution and metabolisation of intact immunoglobulins or their fragments (Thomas et al., 1989) . Given this situation, the presence of a radioactive a-or ,B-emitter or a toxic drug coupled to the MAb is likely to result in extensive destruction of non-tumour tissues.
It may be possible to circumvent these problems using a two phase approach (Bagshawe, 1987; Bagshawe et al., 1988; Hnatowich et al., 1987 Hnatowich et al., , 1989 Senter et al., 1988; Le Doussal et al., 1989; Goodwin et al., 1988) a procedure pioneered in the 70s by Philpott et al. (1973) , which has recently become the focal point of renewed interest. This approach involves a long term non-toxic targeting phase with a modified MAb and a second short term binding of a toxic molecule to the MAb or site specific activation of a small hydrophilic prodrug.
In this report we show that it is possible to target significant amounts of MAb to human colon and pancreatic carcinoma xenografts and to retain the MAb for many days at the tumour site. If such an MAb would have two arms with different specificities, one against the tumour, the second against a small hydrophilic metal chelate, it should be possible to target a quickly-distributing and penetrating chelate very efficiently to the tumour. Because of its short plasma half life and its complete extracellular distribution, a mole- This paper reports the isolation of high affinity MAbs directed against DTPA-Y-90 and the production of bispecific antitumour x anti-DTPA-Y-90 MAbs which should allow us to optimise the conditions for two phase radioimmunotherapy.
Materials and methods

Immunohistochemical investigations
Thin sections (6 ttm) from cryopreserved human tumour xenografts were investigated using the highly sensitive APAAP-technique (Cordell et al., 1984) (Bosslet et al., 1986 each day for 10 consecutive days. Tumours were resected at various days after the final injection and processed for immunohistochemical investigations.
Production of DTPA-specific MAb As immunogen, 19 moles of SCN-benzyl-DTPA were coupled to 1 mole of human serum albumin (HSA-benzyl-DTPA) (Brechbiel et al., 1986 (Kohler & Milstein, 1975) using the SP20/Ag4 myeloma cells (Shulman et al., 1978) as a fusion partner.
Screening of hydridomas Hybridoma supernatants were screened for the presence of anti-HSA-benzyl-DTPA-Y MAb using an ELISA system in which the immunogen was attached to the solid phase (50 ng well-') of round bottom polystyrol microtitre plates (Fa. Nunc). Bound MAb was detected using an alkaline phosphatase labelled goat anti-mouse Ig antibody combined with the alcohol dehydrogenase-diaphorase amplification system (Stanley et al., 1985) .
MAb purification Hybridomas were cultured in serum free Iscoves medium and MAb was purified from the supernatants according to Ey et al. (1978 (Bosslet et al., 1990) was added. After washing, the amount of bound bispecific MAb was visualised using the avidin-biotin peroxidase system (Vector, Burlingname).
Double anti-idiotype chromatography Anti-idiotypic MAbs (anti-ids) specific for MAb BW 431, BW 494 and BW 2050/174 were generated as described (Bosslet et al., 1990) . Protein A sepharose purified anti-ids were covalently coupled to CNBr-activated sepharose at a concentration of 6.5 mg MAb ml-' gel according to the method described by van Eijk et al. (1976) . Ammonium sulfate precipitated and desalted quadroma supernatants were loaded, with a speed of 1.5 ml min-' onto columns containing 70 ml of anti-id coupled gel. After extensive washing with PBS, pH 7.2, specifically bound idiotypic MAb was eluted using 100 mM citrate buffer, pH 2.0, containing 50 g I' sucrose. The eluated fractions were pooled, neutralised and then loaded onto the second anti-id column.
Quantitative binding assay in antigen excess Increasing amounts of antigen were added to 200 ng of purified bispecific MAb. Antigen consisted either of formaldehyde fixed GIT-mucin expressing pancreatic tumour cell suspensions or HSA-methyl-benzyl-DTPA-Y coupled to CNBr activated sepharose gel. After a 4 h incubation at RT the antigen was spun down and the amount of unbound MAb in the supernatant was determined using a quantitative ELISA specific for mouse IgG. The fraction of unbound MAb detectable in the supernatant in antigen excess represents the inactive fraction of the purified MAb preparation.
Generation of Y-90 chelate complexes The commercially available chelates EDTA and DTPA as well as DOTA (Desreux, 1980) , a generous gift of Dr 0. Gansow, NCI, USA, were complexed with Y-90 (Isocommerz, GDR). Briefly, Y-90 was incubated with a 106, 2 x 104 or 2 x 105 molar excess of EDTA, DTPA or DOTA, respectively. Radiochemical purity was determined with silica gel chromatography using a 10% ammoniumacetate/methanol solvent mixture (1/1). The EDTA-Y-90 or DTPA-Y-90 complexes contained less than 5%, or less than 2% free Y-90, respectively. In contrast, the DOTA-Y-90 complex contained about 50% free Y-90 which was removed by incubation and centrifugation using a cation-exchange resin (Dowex 1 x 8, 50-100 mesh, H+ form). The final radiochemical purity of the DOTA-Y-90 complex was better than 95%. (Bosslet et al., 1986 penetrated and bound to the colon carcinoma tissue ( Figure Ic) indicating that the MAb BW 494 which had penetrated the tumour, remained there for a long period of time. Essentially identical data were obtained using the CEA specific MAb BW 431 indicating that penetration and long term retention of MAbs in human carcinoma xenografts is in principal possible. MAb BW 227, selective for a mycoplasma associated epitope, did not bind to the tumour tissue at any point investigated ( Figure Id) . Incubation of the CoCa4 tissue sections with MAb BW 494 prior to addition of the anti-mouse IgG, second antibody resulted in only marginally stronger staining (Figure le) and the binding of this variant was visualised using an anti IgG2a selective second antibody system. An essentially identical staining reaction was seen (Figure 1f) (Reardan et al., 1985) , we produced these MAbs ourselves using HSA-benzyl-DTPA-Y as immunogen (see Material and methods). The arising clones were screened using a direct binding ELISA on HSA-benzyl-DTPA-Y solid phase or a competition ELISA. Out of 70 clones five were selected and the binding inhibition data for these clones are presented in Table I . The individual MAbs showed different strengths of binding to the various chelates. In contrast to our expectation, DTPA-Y was not the best inhibitor. From the Y-chelates investigated the EDTA-Y was the best inhibitor. Some MAbs were also efficiently inhibited by uncomplexed DTPA or EDTA or their complexes formed with irrelevant ions. Especially DTPA-In was a very efficient inhibitor suggesting it for diagnostic purposes. Structurally related substances like diaminoethan or transaconitic acid had no significant inhibitory effect, indicating that the MAbchelate binding is not simply due to charge or hydrophobic interactions, but seems to be more complex. Out of the five MAbs presented in Table I , MAb BW 2050/174 was selected for further use because of its very efficient binding to EDTA-Y and DTPA-In as well as its reasonable binding to DTPA-Y.
Construction of bispecific MAbs
As tumour specific MAbs, MAb BW 431 directed against CEA and MAb BW 494 directed against the GIT-mucin (Bosslet et al., 1986) were chosen. In clinical trials both MAbs have been shown to localise colorectal, stomach, and pancreas carcinomas in patients. The hybridomas 431 and 494 were selected for HGPRT deficiency and each was fused with hybridoma 2050/174 selected for TK deficiency (see Material and methods). The quadromas were selected in HAT medium and screened for the presence of bispecific MAb using a specifically developed antigen-antiidiotype ELISA system (see Materials and methods). Here the detailed data obtained in the BW 494 x BW 2050/174 system are presented:
Sixty-two quadromas were obtained in the fusion between hybridoma 494 and 2050/174 and 29 of these produced bispecific MAbs. Quadroma DF 28/5 was selected because of the high titre (1:32) of its supernatant in the antigen-antiidiotype ELISA as well as its production rate of 20 ltg MAb 10-6 cells/24 h. After cloning by limited dilution, 74% of the clones produced bispecific MAb. Eighty-six percent were positive after a second round of cloning and after a third round 95% of the clones secreted >20 tg MAb ml1. This quadroma remained stable for 30 passages in mass culture.
Using anti-idiotype chromatography with two consecutive columns bearing either an anti-idiotypic MAb to BW 494 and anti-idiotypic MAb to BW 2050/174, bispecific MAb from quadroma supernatants could be isolated essentially free from the nine potentially arising non bispecific molecules (Milstein & Cuello, 1983) . This is demonstrated by the results of a binding assay carried out in antigen excess, in which increasing amounts of GIT-mucin or HSA-benzyl-DTPA-Y were incubated with constant amounts of bispecific MAb. Measurements of unbound MAb indicated that greater than 95% of the preparation consisted of bispecific immunoreactive molecules (Figure 2a,b) . After having shown that it is possible to obtain purified bispecific MAb with greater than 95% immunoreactivity for both arms, we evaluated the in vivo stability of the Y-90 chelates, the second component needed for two phase radioimmunotherapy.
In vivo stability of Y-chelates To investigate the stability of preformed EDTA-Y-90, DTPA-Y-90 or DOTA-Y-90 chelates in vivo, 850kBq, 400 kBq or 300 kBq of the respective chelates were injected i.v. into Wistar rats and the bone as well as the bone marrow 
Discussion
The present report introduces a two phase radioimmunotherapy approach which consists of essentially three steps: The experimental data generated in this study support the assumptions made in the first step. We have shown that it is possible to obtain a significant tissue penetration of solid human carcinoma xenografts after 10 daily i.v. injections of high doses of tumour specific MAb. This finding is in contrast to reports showing that a single i.v. injection of radiolabelled MAb leads to binding of MAb only at the rim of the tumour (Del Vecchio et al., 1989; Pervez et al., 1988; Ong & Mathe, 1989) . The immunohistochemical methodology applied in our work allowed an exact localisation of the MAb to the tumour cell membranes, the interstitial space and the lumen, Figure Ic) . This tissue penetration and long term retention phase was shown to be similar to two distinct MAbs, the CEA-specific MAb BW 431 and the GIT-mucin specific MAb BW 494 (Bosslet et al., 1986 (Figure If) . Tissue penetration could perhaps be optimised by using MAb fragments or genetically engineered domain antibodies (Huse et al., 1989; Ward et al., 1989) .
The second step of our two phase radioimmunotherapy approach was experimentally proven by Steinstraesser et al. (1988) who showed that biosynthetically as well as In-111-labelled MAb is metabolised in the liver parenchymal cells, i.e. no more accessible from outside.
The efficiency of the third step is highly dependent on the affinity of the anti-chelate arm of the bispecific MAb for the chelate metal complex. Therefore we tried to generate high affinity anti-DTPA-Y MAbs by immunising Balb/c mice with a specially synthesised highly immunogenic hapten carrier complex. Immunisation with this HSA-benzyl-DTPA-Y complex resulted in the generation of 350 clones producing MAbs binding to the immunogen. From these MAbs those which could be inhibited in their binding to the immunogen by free DTPA-Y or related compounds were selected (Table I) Bispecific MAb could be purified from the quadroma supernatant using double anti-idiotype chromatography. The immunoreactivity of this bispecific anti-GIT mucin x anti-DTPA-Y-90 MAb was greater than 95% for each individual arm and is exceptionally high when compared to bispecific MAbs purified by other methods Smith et al., 1990; Lenz & Weidle, 1990) .
Future experiments will be needed to determine whether the affinity of the single anti-CEA or anti-GIT-mucin arm of the bispecific MAb is sufficient to enable these reagents to penetrate and be retained in the tumour as efficiently as the mono-specific bivalent MAbs. The most critical point in our approach is probably the affinity of the anti-DTPA-Y arm for the free DTPA-Y. To be effective this chelate has to bind very efficiently in vivo to the anti-DTPA-Y arm of the bispecific MAb present on the tumour. The small hydrophilic DTPA-Y should be trapped by the anti-DTPA-Y arm like a small hormone (Reubi et al., 1987; Krenning et al., 1989) by its receptor and this should lead to a quick and efficient localisation to the tumour. However, this is only possible if the i.v. injected Y-90 chelate is stable in vivo and not nonspecifically trapped in normal tissues. Comparative in vivo studies in rats using EDTA-Y-90, DTPA-Y-90 and DOTA-Y-90 showed that because of its stability, the most suitable chelate for in vivo use is the DTPA-Y-90 chelate. Y-90 levels in mineralised bone 24h after injection of EDTA-Y-90 or DOTA-Y-90 were 100-fold higher than after injection of DTPA-Y-90 (Table II) .
The reagents presented in this paper may overcome the problems of tumour heterogeneity and limited MAb percolation (Jain, 1987; Bosslet et al., 1990) in human tissues. The long range radiation of Y-90 (9 mm) stably chelated to DTPA combined with the high avidity bispecific intact MAb should allow the development of a new and more effective radioimmunotherapy regimen for carcinomas.
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